mighty, This is what Dr J said Ed: Alzheimer’s and LL.

New Post Public Reply Private Reply Replies (0) Message Board
chazzledazzle mightycydy #141538
635
mighty,

This is what Dr J said Ed: Alzheimer’s and LL. I also think I think you have the right paper from 6/22. Both are mice related. The paper reports an intensely prosecuted mice study regarding CCR5/CCL5 presence and exclusion, and the memory results in test subject, mice.

Here’s Dr J from yesterday.

“And given the world's highest safety profile of Leronlimab to date, together with data from a recent preclinical study suggesting that blocking CCR5 in mice can rescue memory deficits, I believe a pilot study in Alzheimer's Disease is now justified.”

Investors Hangout: https://investorshangout.com/post/view?id=667...z8Tkf8UHFp

Here is a link to the paper you shared in case others want to read.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197199/

Ohm20 came with this paper from 11/21. Not the same, but also tested with Maravoric. Mainly going down the tech Tau/Amyloid path. I’ll share a few Maravoric citations from both later.
https://molecularneurodegeneration.biomedcent...21-00500-0

Here’s a couple of key passages from your 6/22 paper. They did a fairly exhaustive study. If they noticed a result in young mice, they tested it in old mice. If they noticed in CCR5 neg mice, they tested it in CCR5 knockout mice (Maravoric) Etc. Quite impressive results.

“Here, we report that a delayed (12-24h) increase in the expression of the C-C chemokine receptor type 5 (CCR5), an immune receptor well known as a co-receptor for HIV infection6,7, following the formation of a contextual memory, determines the duration of the temporal window for associating or linking that memory with subsequent memories.”

“CCR5 has been extensively studied in the context of inflammatory responses and HIV infection6,7. However, comparatively little is known about its role in learning and memory. Both CCR5 and its ligand CCL5 are highly enriched in the CA1 region of the hippocampus14–16, and CCR5 is a negative regulator of CREB activation and neuronal excitability15,17. Here, we demonstrate that a gradual increase in the expression of CCL5/CCR5 following memory formation closes the temporal window for memory linking, thus segregating memories that are temporally distinct.”

“To determine whether CCR5 modulates the temporal window for contextual memory linking1, we first exposed the mice to one context (context A) and either 5h, 1, 2 or 7 days later we exposed the mice to a second context (context B) (Fig. 2a). Two days later, the mice were given an immediate shock in context B, and then contextual memory linking was tested 2d later in context A.”

“During the contextual memory linking test, only the control group, but not the Opto-CCR5 group, showed evidence of memory linking (i.e., higher freezing in context A, that the mice experienced 5h before context B, compared to a novel context; Fig. 2e), confirming that increasing neuronal CCR5 activity specifically after exposure to context A is sufficient to impair contextual memory linking without impairing memory for context B.”

“Thus, two very different manipulations that decreased the levels of CCR5 (shRNA-mediated knockdown and a knockout) extended the temporal window for memory linking. Similar to Ccr5−/− mice, Ccl5 knockout (Ccl5−/−) mice also showed an extended linking window (Extended Data Fig. 6g), indicating that CCL5 is critical for CCR5 regulation of memory linking…Altogether, our results show that increasing or inhibiting CCR5 signaling impaired or extended (respectively) the temporal window for contextual memory linking, demonstrating a key role for CCR5 in setting the duration for the memory linking window.”

“This result supports the hypothesis that CCR5 activation excludes neurons from memory ensembles.”

“Altogether, the results presented suggest that the increase in CCR5 expression and signaling after learning prevents subsequent memories from being allocated to the neuronal ensemble encoding the initial memory, thus reducing the overlap between the two memory ensembles, and consequently attenuating memory linking.”

“CCR5 and CCL5 expression in peripheral immune cells increases with age31,32. Similar increases in aging neurons could contribute to age-related decreases in contextual memory linking1. To test this hypothesis, we measured hippocampal Ccr5 and Ccl5 expression in 16~18-month-old mice (middle-aged), an age in which mice still show intact contextual conditioning, but deficits in contextual memory linking”

“To test the effect of pharmacologically blocking CCR5 activity on contextual memory linking in middle-aged mice, maraviroc (an FDA approved CCR5 antagonist used for HIV treatment; Extended Data Fig. 4d–f)33 was infused to dCA1 of these mice 1h before they were exposed to context B in a contextual memory linking experiment with a 5h interval. Unlike control mice, maraviroc-treated mice showed memory linking (Fig. 4h). Thus, blocking CCR5 with maraviroc ameliorates the memory linking deficits in middle-aged mice. Altogether these results support a role for CCR5 expression in closing the temporal window for memory linking as well as in age-related deficits in memory linking.”

“In summary, the findings reported here show that a delayed (12-24h) increase in CCL5/CCR5 signaling in dCA1 neurons of a given memory ensemble closes the temporal window for memory linking. CCR5 activation decreases neuronal excitability, thus negatively regulating memory allocation. This change in memory allocation decreases the overlap between memory ensembles, and therefore impairs the ability of one memory to trigger the recall of the other, thus closing the temporal window for memory linking (Extended Data Fig. 10). Remarkably, our findings also show that an age-related increase in CCL5/CCR5 expression leads to impairments in memory linking in middle-aged mice that could be reversed with an FDA approved drug that inhibits this receptor, a result with significant clinical implications. All together the findings reported here provide the first insights into the molecular and cellular mechanisms that close the temporal window for memory linking, thus segregating the memories for events that are temporally distinct.”

Conclusion is just what Dr J said about resources.
“The challenge of course is that CytoDyn is just emerging from a two year clinical hold and doesn't have the resources to do everything we'd like. We're also keenly aware the need to stay focused and not try to do too much all at once.

But I believe we have this going forward, “Anything Maravoric can do, we can do better!” Like 100.83% better!

Running out of time for Ohms paper, but here’s a Maravoric citation from it.

“Abstract
Background
Neurocognitive impairment is present in 50% of HIV-infected individuals and is often associated with Alzheimer’s Disease (AD)-like brain pathologies, including increased amyloid-beta (Aβ) and Tau hyperphosphorylation. Here, we aimed to determine whether HIV-1 infection causes AD-like pathologies in an HIV/AIDS humanized mouse model, and whether the CCR5 antagonist maraviroc alters HIV-induced pathologies.
Methods
NOD/scid–IL-2Rγcnull mice engrafted with human blood leukocytes were infected with HIV-1, left untreated or treated with maraviroc (120 mg/kg twice/day). Human cells in animal’s blood were quantified weekly by flow cytometry. Animals were sacrificed at week-3 post-infection; blood and tissues viral loads were quantified using p24 antigen ELISA, RNAscope, and qPCR. Human (HLA-DR+) cells, Aβ-42, phospho-Tau, neuronal markers (MAP 2, NeuN, neurofilament-L), gamma-secretase activating protein (GSAP), and blood-brain barrier (BBB) tight junction (TJ) proteins expression and transcription were quantified in brain tissues by immunohistochemistry, immunofluorescence, immunoblotting, and qPCR. Plasma Aβ-42, Aβ-42 cellular uptake, release and transendothelial transport were quantified by ELISA.
Results
HIV-1 significantly decreased human (h)CD4+ T-cells and hCD4/hCD8 ratios; decreased the expression of BBB TJ proteins claudin-5, ZO-1, ZO-2; and increased HLA-DR+ cells in brain tissues. Significantly, HIV-infected animals showed increased plasma and brain Aβ-42 and phospho-Tau (threonine181, threonine231, serine396, serine199), associated with transcriptional upregulation of GSAP, an enzyme that catalyzes Aβ formation, and loss of MAP 2, NeuN, and neurofilament-L. Maraviroc treatment significantly reduced blood and brain viral loads, prevented HIV-induced loss of neuronal markers and TJ proteins; decreased HLA-DR+ cells infiltration in brain tissues, significantly reduced HIV-induced increase in Aβ-42, GSAP, and phospho-Tau. Maraviroc also reduced Aβ retention and increased Aβ release in human macrophages; decreased the receptor for advanced glycation end products (RAGE) and increased low-density lipoprotein receptor–related protein-1 (LRP1) expression in human brain endothelial cells. Maraviroc induced Aβ transendothelial transport, which was blocked by LRP1 antagonist but not RAGE antagonist.
Conclusions
Maraviroc significantly reduced HIV-induced amyloidogenesis, GSAP, phospho-Tau, neurodegeneration, BBB alterations, and leukocytes infiltration into the CNS. Maraviroc increased cellular Aβ efflux and transendothelial Aβ transport via LRP1 pathways. Thus, therapeutically targeting CCR5 could reduce viremia, preserve the BBB and neurons, increased brain Aβ efflux, and reduce AD-like neuropathologies.”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 29

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 123

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 31

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 88

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 47

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
FCC Opens Prison Jamming Door, Raising Execution Stakes

Updated Category News Views 98

A Regulatory Door Finally Moves Five hundred thousand contraband phones is the sort of estimate that makes a rule change hard to shrug off. On November 19, 2026, the Federal Communications Commission adopted its Third Report and Order in GN Docket No. 13-111, allowing RF jamming in state and local correctional facilities for the first time. That is a meaningful break from...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 84

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Dynamics of the Automated Sortation System Market

Updated Category News Views 95

The Growth of the Automated Sortation System Market The automated sortation systems market is on a rapid ascent, projected to rise significantly and reach an estimated USD 5.68 billion by 2032. This thriving market, valued at approximately USD 4.00 billion in the previous year, demonstrates a vigorous compound annual growth rate (CAGR) of 3.99% from 2024 to 2032. The...

Continue Reading
Advancing Biopharmaceutical Manufacturing with New Ontologies

Updated Category News Views 148

Introducing Advanced Biopharmaceutical Manufacturing Ontologies In a groundbreaking development for the biopharmaceutical industry, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and Open Applications Group, Inc. (OAGi) have unveiled a set of innovative ontologies aimed at improving data interoperability and analytics. This...

Continue Reading
Illinois Tool Works Prepares for Third Quarter Earnings Call

Updated Category News Views 46

Illinois Tool Works Announces Earnings Webcast Schedule Illinois Tool Works Inc. (NYSE: ITW), a prominent name in global manufacturing, is set to release its third quarter results. The company will issue the results on a Wednesday morning at 7:00 a.m. CDT. Following this important announcement, ITW will host a webcast to discuss the outcomes and insights from their...

Continue Reading
Parry Labs Collaborates with Marines on Advanced Data Solutions

Updated Category News Views 158

Parry Labs Collaborates with Marines on Advanced Data Solutions Parry Labs, a leading defense technology firm known for its innovative hardware and digital infrastructure, has engaged with the United States Marine Corps to explore advanced data transfer techniques. During a recent demonstration involving the Joint Staff J6, Parry Labs worked on the Phantom network gateway...

Continue Reading
Discover Autonomix Medical’s Groundbreaking Presentation at EuroPCR

Updated Category News Views 122

Autonomix Medical's Innovative Contribution to EuroPCR Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneering medical device company, is making waves in the field of interventional cardiology. With a focus on precision nerve-targeted treatments, the company has announced exciting developments that will be showcased in a poster presentation at the renowned EuroPCR. The Event...

Continue Reading